Skip to content
All Sections
Subscribe Now
69°F
Thursday, August 22nd 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
69°F
Thursday, August 22nd 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Pike Outlets shooting
Driver's licenses to go mobile
Long Beach's Olympic moment
Walker killed by dogs
Joe Jost's turns 100 ð
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by CEL-SCI Corporation
< Previous
1
2
Next >
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
August 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Closing of $10.8 Million Offering
July 29, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Pricing of $10.8 Million Offering
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Appoints Robert Watson as Chairperson of the Board
July 08, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
June 18, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
June 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
May 16, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
May 08, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
April 23, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
March 19, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Issues Letter to Shareholders
March 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
February 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
February 13, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
February 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
January 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
December 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
December 04, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
November 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
November 16, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Issues Letter to Shareholders
October 30, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
October 24, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
October 23, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
October 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
October 05, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
September 26, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
August 11, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Closing of Public Offering
July 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
CEL-SCI Announces Pricing of Public Offering
July 17, 2023
From
CEL-SCI Corporation
Via
Business Wire
Tickers
CVM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close